Q-omics provides the consensus-scored CSKMT profile across patient tissues and cancer cell-line models. CSKMT expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CSKMT is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, CSKMT RNA expression shows 17,864 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and BLCA as cancer lineages where CSKMT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CSKMT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CSKMT survival associations across molecular data types. CSKMT RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CSKMT RNA expression–survival associations across cancer types. High CSKMT expression shows unfavorable associations in ACC, LIHC, COAD and LAML, but favorable associations in BRCA and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CSKMT RNA expression.
This table summarizes CSKMT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for CSKMT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CSKMT shows higher tumor expression in BLCA, COAD, LIHC, LUSC, STAD and BRCA. The BLCA box plot shows higher CSKMT RNA expression in tumor versus normal tissue (log2 FC = +0.933, t-test p < 0.001).
This table shows molecular features associated with CSKMT in patient tissues and cancer cell lines. In patient samples, CSKMT shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CSKMT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
